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Résumé en
anglais
OBJECTIVE: Erythropoietin used to correct anaemia in chronic kidney disease (CKD)
has been shown to increase blood pressure (BP) in CKD patients and experimental
animals. Endothelin (ET)-1 expression is increased in CKD animals and patients, and
enhanced by erythropoietin. Erythropoietin-induced BP rise was blunted by ETA
receptor blockers. This study was designed to determine whether preexisting
endothelin (ET)-1 overexpression is required for erythropoietin to cause adverse
vascular effects and whether this could be prevented by exercise training.
METHODS: Eight to 10-week old male wild-type mice and mice with endothelial-
specific ET-1 overexpression (eET-1) were treated or not with EPO (100 IU/kg, SC, 3
times/week). eET-1 was subjected or not to swimming exercise training (1 h/day, 6
days/week) for 8 weeks. SBP, mesenteric artery endothelial function and remodelling,
NADPH oxidase activity, reactive oxygen species (ROS) generation, vascular cell
adhesion protein (VCAM)-1, monocyte/macrophage infiltration, T regulatory cells
(Tregs) and tissue ET-1 and plasma endothelin were determined. RESULTS:
Erythropoietin increased SBP by 24 mmHg (P < 0.05) and decreased by 25%
vasodilatory responses to acetylcholine (P < 0.01) in eET-1 mice. Erythropoietin
enhanced ET-1 induced increase in resistance artery media/lumen ratio (31%, P <
0.05), aortic NADPH oxidase activity (50%, P < 0.05), ROS generation (93%, P <
0.001), VCAM-1 (80%, P < 0.01) and monocyte/macrophage infiltration (159%, P <
0.001), and raised plasma and aortic ET-1 levels (>/=130%, P < 0.05). EPO had no
effect in wild-type mice. Exercise training prevented all of the above (P < 0.05).
CONCLUSION: Erythropoietin-induced adverse vascular effects are dependent on
preexisting elevated ET-1 expression. Exercise training prevented erythropoietin-
induced adverse vascular effects in part by inhibiting ET-1 overexpression-induced
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